Omeros (NASDAQ: OMER)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Omeros Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Omeros Company Info
Omeros Corporation is a clinical-stage Biopharmaceutical Company engaged in discovering developing and commercializing products focused on inflammation and disorders of the central nervous system.
News & Analysis
A $200 million milestone payment sparked a rally in the biopharma's shares this week.
The Omeros will now be able to fund operations at least through 2025.
A positive regulatory development is powering the biotech's shares higher today.
It's reverting to where it was before its massive uptick last week.
Bad news the company received today from the FDA surprised investors more than it probably should have.
The narsoplimab program hasn't proceeded as swimmingly as investors thought.
The biotech stock was part of a larger Wall Street sell-off.
The biopharma announced the pricing of a public offering of common stock and debt offering.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/28/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
OMER earnings call for the period ending March 31, 2020.
OMER earnings call for the period ending December 31, 2019.
OMER earnings call for the period ending September 30, 2019.
OMER earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.